Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
Status:
Active, not recruiting
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the efficacy and safety in patients with
gastric adenocarcinoma or adenocarcinoma of esophagogastric junction. The main questions it
aims to answer are:
- Does this therapy have a promising efficacy?
- Does this therapy have a manageable toxity? Participants will receive fruquintinib plus
sintilimab as first-line therapy for gastric cancer.